Results of follow‐up muscle mass measurements have also been described in advanced NSCLC patients who were receiving targeted therapies (EGFR or ALK tyrosine kinase inhibitors)20 or who were receiving immunotherapy (i.e., anti‐PD1/PDL1 monoclonal antibodies).24, 25. The gene discussed is ALK; the disease is non-small cell lung carcinoma.